

09/046,840  
attachment to  
Page # 7

\*\*\*\*\*  
FILE 'USPAT' ENTERED AT 15:51:54 ON 13 MAR 1999

\*\*\*\*\*  
\* WELCOME TO THE \*  
\* U. S. PATENT TEXT FILE \*  
\*\*\*\*\*

=> s retrovir? and adeno-associated

5866 RETROVIR?  
1005 ADENO  
837573 ASSOCIATED  
452 ADENO-ASSOCIATED  
(ADENO(W) ASSOCIATED)  
L1 427 RETROVIR? AND ADENO-ASSOCIATED

=> s l1 and vector? and packag?

76009 VECTOR?  
186712 PACKAG?  
L2 311 L1 AND VECTOR? AND PACKAG?

=> s l2 and packaging cell line?

80764 PACKAGING  
225668 CELL  
1601068 LINE?  
387 PACKAGING CELL LINE?  
(PACKAGING(W) CELL(W) LINE?)  
L3 94 L2 AND PACKAGING CELL LINE?

=> s l3 and integr?

767219 INTEGR?  
L4 89 L3 AND INTEGR?

=> d 14,1-89,cit

1. 5,874,556, Feb. 23, 1999, Hybrid genes for use in the production of T.sub.H -independent cytotoxic T cells; Stephen D. Lupton, et al., 536/23.1; 435/69.1, 69.5, 69.52, 69.7, 252.3, 320.1, 363, 366, 372, 372.3; 536/23.4, 23.52 [IMAGE AVAILABLE]

2. 5,872,005, Feb. 16, 1999, **Packaging cell lines for adeno-associated viral vectors**; Qing Wang, et al., 435/320.1, 369 [IMAGE AVAILABLE]

3. 5,871,982, Feb. 16, 1999, Hybrid adenovirus-AAV virus and methods of use thereof; James M. Wilson, et al., 435/235.1, 320.1, 325 [IMAGE AVAILABLE]

4. 5,871,726, Feb. 16, 1999, Tissue specific and tumor growth suppression by adenovirus comprising prostate specific antigen; Daniel Robert Henderson, et al., 424/93.2, 93.6; 435/320.1, 325, 456 [IMAGE AVAILABLE]

5. 5,869,622, Feb. 9, 1999, Monoclonal antibodies to the pur protein;

Edward M. Johnson, et al., 530/388.85, 388.1, 389.1, 389.7 [IMAGE AVAILABLE]

6. 5,869,248, Feb. 9, 1999, Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences; Yan Yuan, et al., 435/6; 536/23.2 [IMAGE AVAILABLE]

7. 5,869,040, Feb. 9, 1999, Gene therapy methods and compositions; Xiao-Oiang Oin, 424/93.21; 435/69.1, 320.1, 366; 536/23.5 [IMAGE AVAILABLE]

8. 5,869,035, Feb. 9, 1999, Methods and compositions for inducing complement destruction of tissue; Charles J. Link, Jr., et al., 424/93.7, 93.21, 277.1; 435/320.1; 514/44 [IMAGE AVAILABLE]

9. 5,861,488, Jan. 19, 1999, Compositions and methods for treating sickle cell disease; Philippe LeBoulch, et al., 530/385; 435/69.1 [IMAGE AVAILABLE]

10. 5,861,372, Jan. 19, 1999, Aggregate angiostatin and method of use; M. Judah Folkman, et al., 514/2, 12; 530/350, 412, 417, 422 [IMAGE AVAILABLE]

11. 5,861,290, Jan. 19, 1999, Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders; Mark A. Goldsmith, et al., 424/93.2; 435/320.1; 514/44; 536/23.1, 23.2, 23.5, 23.53, 23.6, 23.7, 23.72, 24.1, 24.5 [IMAGE AVAILABLE]

12. 5,858,990, Jan. 12, 1999, Fas ligand compositions for treatment of proliferative disorders; Kenneth Walsh, 514/44; 435/6, 69.1, 320.1, 375, 377 [IMAGE AVAILABLE]

13. 5,858,355, Jan. 12, 1999, IRAP gene as treatment for arthritis; Joseph C. Glorioso, et al., 424/93.21, 93.2; 514/44 [IMAGE AVAILABLE]

14. 5,856,152, Jan. 5, 1999, Hybrid adenovirus-AAV **vector** and methods of use therefor; James M. Wilson, et al., 435/457, 320.1, 369 [IMAGE AVAILABLE]

15. 5,854,221, Dec. 29, 1998, Endothelial cell proliferation inhibitor and method of use; Yihai Cao, et al., 514/12; 530/350, 380 [IMAGE AVAILABLE]

16. 5,854,067, Dec. 29, 1998, Hexokinase inhibitors; Christopher B. Newgard, et al., 435/366, 4, 6, 91.1, 91.31, 183, 320.1, 325; 536/23.1, 24.31, 24.5 [IMAGE AVAILABLE]

17. 5,851,826, Dec. 22, 1998, Helper virus-free herpesvirus **vector packaging** system; Cornel Fraefel, et al., 435/325, 69.1, 320.1, 456, 465 [IMAGE AVAILABLE]

18. 5,851,788, Dec. 22, 1998, Nucleic acid encoding a family of acetyl-coenzyme-A transporter proteins, and products related thereto; Minoru Fukuda, et al., 435/29, 6, 69.1, 320.1, 325, 975; 536/23.5, 24.3, 24.31 [IMAGE AVAILABLE]

19. 5,843,723, Dec. 1, 1998, Alphavirus **vector** constructs; Thomas W. Dubensky, Jr., et al., 435/69.3, 235.1, 320.1, 325 [IMAGE AVAILABLE]

20. 5,837,682, Nov. 17, 1998, Angiostatin fragments and method of use; M. Judah Folkman, et al., 514/12, 2; 530/300, 350 [IMAGE AVAILABLE]

21. 5,837,510, Nov. 17, 1998, Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders; Mark A. Goldsmith, et al., 435/455; 424/93.2; 435/320.1, 456; 514/44;

536/23.1, 23.2, 23.5, 23.53, 23.6, 23.7, 23.72, 24.1, 24.5 [IMAGE AVAILABLE]

22. 5,837,507, Nov. 17, 1998, Hox-induced enhancement of in vivo and in vitro proliferative capacity and gene therapeutic methods; Corey Largman, et al., 424/93.21; 435/325, 372, 456, 458 [IMAGE AVAILABLE]

23. 5,837,484, Nov. 17, 1998, Stable cell lines capable of expressing the **adeno-associated** virus replication gene; James P. Trempe, et al., 435/69.1, 235.1, 320.1, 369 [IMAGE AVAILABLE]

24. 5,834,306, Nov. 10, 1998, Tissue specific hypoxia regulated therapeutic constructs; Keith A. Webster, et al., 435/320.1; 536/24.1 [IMAGE AVAILABLE]

25. 5,833,991, Nov. 10, 1998, Glycine-containing sequences conferring invisibility to the immune system; Maria G. Masucci, 424/185.1, 192.1, 230.1; 530/350; 536/23.4 [IMAGE AVAILABLE]

26. 5,830,755, Nov. 3, 1998, T-cell receptors and their use in therapeutic and diagnostic methods; Michael Nishimura, et al., 435/325; 424/93.2; 435/6, 7.23, 69.1, 320.1; 530/387.7; 536/23.1 [IMAGE AVAILABLE]

27. 5,830,461, Nov. 3, 1998, Methods for promoting wound healing and treating transplant-associated vasculopathy; Timothy R. Billiar, et al., 424/94.4, 94.1; 435/189 [IMAGE AVAILABLE]

28. 5,827,642, Oct. 27, 1998, Rapid expansion method ("REM") for in vitro propagation of T lymphocytes; Stanley R. Riddell, et al., 435/2; 424/93.71; 435/372.3, 373, 375, 383, 384, 386 [IMAGE AVAILABLE]

29. 5,824,544, Oct. 20, 1998, Adenovirus **vectors** for gene therapy; Donna Armentano, et al., 435/320.1; 514/44 [IMAGE AVAILABLE]

30. 5,821,235, Oct. 13, 1998, Gene therapy using the intestine; Susan June Henning, et al., 514/44; 424/93.21; 435/69.1, 70.3, 320.1; 604/264, 265, 266 [IMAGE AVAILABLE]

31. 5,817,628, Oct. 6, 1998, Dynorphin a suppression of natural killer cell activity; Mary Jeanne Kreek, 514/13, 15; 530/327, 328 [IMAGE AVAILABLE]

32. 5,814,482, Sep. 29, 1998, Eukaryotic layered **vector** initiation systems; Thomas W. Dubensky, Jr., et al., 435/69.3, 320.1; 536/23.1, 24.1 [IMAGE AVAILABLE]

33. 5,811,298, Sep. 22, 1998, Rep-max protein having anti-oncogenic activity and uses thereof; Ronald DePinho, et al., 435/320.1, 6, 69.1 [IMAGE AVAILABLE]

34. 5,811,275, Sep. 22, 1998, HIV-specific ribozymes; Flossie Wong-Staal, et al., 435/455; 424/93.2, 93.21; 435/320.1, 456; 536/23.1, 24.5 [IMAGE AVAILABLE]

35. 5,811,234, Sep. 22, 1998, Methods and applications for efficient genetic suppressor elements; Igor B. Roninson, et al., 435/6, 456, 463, 469, 471, 472 [IMAGE AVAILABLE]

36. 5,804,445, Sep. 8, 1998, High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor; Allan R. Brasier, 435/375, 243, 325; 530/324 [IMAGE AVAILABLE]

37. 5,804,412, Sep. 8, 1998, Nucleic acids encoding sorting nexins and methods of using same; Gordon N. Gill, et al., 435/69.1, 320.1, 325; 530/300, 350; 536/23.1 [IMAGE AVAILABLE]

38. 5,801,146, Sep. 1998, Compound and method for inhibiting angiogenesis; Donald J. Davidson, 514/12; 530/300, 324, 380 [IMAGE AVAILABLE]
39. 5,798,209, Aug. 25, 1998, Human and mouse very low density lipoprotein receptors and methods for use of such receptors; Lawrence C. B. Chan, 435/6, 91.2; 536/23.1, 24.3, 24.33 [IMAGE AVAILABLE]
40. 5,789,389, Aug. 4, 1998, BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs; Dariusz G. Tarasewicz, et al., 514/44; 536/24.5 [IMAGE AVAILABLE]
41. 5,789,245, Aug. 4, 1998, Alphavirus structural protein expression cassettes; Thomas W. Dubensky, Jr., et al., 435/320.1, 69.1, 325; 536/23.72 [IMAGE AVAILABLE]
42. 5,786,340, Jul. 28, 1998, Gene transfer to the intestine; Susan June Henning, et al., 514/44; 424/93.1 [IMAGE AVAILABLE]
43. 5,786,213, Jul. 28, 1998, Inhibition of endogenous gastrin expression for treatment of colorectal cancer; Pomila Singh, et al., 435/320.1; 424/93.21; 435/69.1, 325; 514/2, 44; 536/23.1, 24.3 [IMAGE AVAILABLE]
44. 5,786,179, Jul. 28, 1998, Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same; Konstantin Kousoulas, et al., 435/69.7, 69.4, 252.3, 320.1, 325; 530/350, 397, 399; 536/23.4, 23.51 [IMAGE AVAILABLE]
45. 5,780,447, Jul. 14, 1998, Recombinant **adeno-associated** viral **vectors**; Arthur W. Nienhuis, 514/44; 424/93.2, 93.21; 435/320.1, 325, 375, 456, 457 [IMAGE AVAILABLE]
46. 5,780,280, Jul. 14, 1998, Recombinant **adeno-associated** virus **vectors**; Jane S. Lebkowski, et al., 435/457, 235.1, 320.1, 465 [IMAGE AVAILABLE]
47. 5,770,690, Jun. 23, 1998, Bax omega protein and methods; Catherine Mastroni Bitler, et al., 530/324, 329, 350 [IMAGE AVAILABLE]
48. 5,766,585, Jun. 16, 1998, Systemic gene treatment of connective tissue diseases with IRAP-1; Christopher H. Evans, et al., 424/93.21, 93.1, 93.2, 529, 534; 435/320.1; 514/44 [IMAGE AVAILABLE]
49. 5,756,684, May 26, 1998, Cloning and expression of PUR protein; Edward M. Johnson, et al., 530/388.21; 435/69.1, 69.7 [IMAGE AVAILABLE]
50. 5,753,500, May 19, 1998, Helper-free stocks of recombinant **adeno-associated** virus **vectors**; Thomas E. Shenk, et al., 435/320.1, 235.1 [IMAGE AVAILABLE]
51. 5,753,499, May 19, 1998, Viral **vector** complexes having adapters of predefined valence; Daniel Meruelo, et al., 435/320.1, 235.1, 456; 514/44 [IMAGE AVAILABLE]
52. 5,750,396, May 12, 1998, Stable virus **packaging cell lines**; Yanping Yang, et al., 435/357, 320.1, 366; 536/23.72, 24.1 [IMAGE AVAILABLE]
53. 5,750,367, May 12, 1998, Human and mouse very low density lipoprotein receptors and methods for use of such receptors; Lawrence C. B. Chan, 435/69.1, 69.6, 70.1, 70.3, 71.1, 243, 320.1, 325, 410; 536/23.1, 23.5, 24.1 [IMAGE AVAILABLE]

54. 5,747,659, May 5, 1998, Fusion gene products encoding avian alpha subunit inhibin protein or an immunogenic fragment thereof, and a carrier protein; William C. Fioretti, et al., 536/23.4; 435/69.4, 69.7, 252.3, 320.1, 325; 536/23.51 [IMAGE AVAILABLE]
55. 5,747,292, May 5, 1998, Chimeric cytokine receptors in lymphocytes; Philip D. Greenberg, et al., 435/69.7, 252.3, 320.1; 530/350; 536/23.4 [IMAGE AVAILABLE]
56. 5,741,706, Apr. 21, 1998, Anti-HIV ribozymes; Markley C. Leavitt, et al., 435/372, 6, 91.31, 320.1, 325, 366; 536/23.1, 23.2, 24.5 [IMAGE AVAILABLE]
57. 5,738,852, Apr. 14, 1998, Methods of enhancing antigen-specific T cell responses; William S. Robinson, et al., 424/199.1, 93.2, 278.1; 435/320.1; 514/44 [IMAGE AVAILABLE]
58. 5,736,388, Apr. 7, 1998, Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells; Sunil Chada, et al., 435/320.1; 424/93.6; 435/235.1; 514/44 [IMAGE AVAILABLE]
59. 5,725,858, Mar. 10, 1998, Methods of enhancing production performance of birds comprising administration of heterologous protein comprising avian alpha-subunit inhibin protein; William C. Fioretti, et al., 424/192.1, 184.1, 185.1, 193.1, 195.11, 198.1; 514/2, 8, 12 [IMAGE AVAILABLE]
60. 5,723,581, Mar. 3, 1998, Murine and human box-dependent myc-interacting protein (Bin1); George C. Prendergast, et al., 530/350, 827, 828 [IMAGE AVAILABLE]
61. 5,723,333, Mar. 3, 1998, Human pancreatic cell lines: developments and uses; Fred Levine, et al., 435/325, 320.1, 377, 378 [IMAGE AVAILABLE]
62. 5,707,618, Jan. 13, 1998, Adenovirus **vectors** for gene therapy; Donna Armentano, et al., 424/93.21, 93.2; 435/320.1; 514/44 [IMAGE AVAILABLE]
63. 5,698,446, Dec. 16, 1997, Methods and compositions for inhibiting production of replication competent virus; Wolfgang M. Klump, et al., 435/350, 320.1, 366 [IMAGE AVAILABLE]
64. 5,698,443, Dec. 16, 1997, Tissue specific viral **vectors**; Daniel Robert Henderson, et al., 435/320.1; 424/93.21; 435/235.1, 252.3, 456; 514/2, 44 [IMAGE AVAILABLE]
65. 5,693,508, Dec. 2, 1997, **Retroviral** expression **vectors** containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats; Lung-Ji Chang, 435/6, 69.1, 320.1, 456, 465; 536/24.1 [IMAGE AVAILABLE]
66. 5,691,306, Nov. 25, 1997, Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production; John J. M. Bergeron, et al., 514/11; 435/70.1 [IMAGE AVAILABLE]
67. 5,691,176, Nov. 25, 1997, Recombinant **adeno-associated** virus **vector packaging** cells and methods for use; Jane S. Lebkowski, et al., 435/457, 235.1, 320.1, 325, 465; 536/23.1 [IMAGE AVAILABLE]
68. 5,688,773, Nov. 18, 1997, Method of selectively destroying neoplastic cells; E. Antonio Chiocca, et al., 514/44; 424/93.1, 93.21; 435/320.1 [IMAGE AVAILABLE]
69. 5,681,731, Oct. 28, 1997, Method for producing recombinant **adeno-associated** virus **vectors**; Jane S. Lebkowski, et al.,

435/457, 320.1, 354, 366; 536/23.1 [IMAGE AVAILABLE]

70. 5,672,686, Sep. 30, 1997, Bcl-Y - specific antibodies; Thomas D. Chittenden, 530/387.9, 388.2, 389.1, 391.3 [IMAGE AVAILABLE]

71. 5,672,479, Sep. 30, 1997, Methods for identifying compounds that bind to PUR protein; Edward M. Johnson, et al., 435/7.1, 7.23, 7.71, 7.93; 530/300, 358 [IMAGE AVAILABLE]

72. 5,670,488, Sep. 23, 1997, Adenovirus **vector** for gene therapy; Richard J. Gregory, et al., 514/44; 424/93.2; 435/320.1 [IMAGE AVAILABLE]

73. 5,670,361, Sep. 23, 1997, HIV-specific ribozymes; Flossie Wong-Staal, et al., 435/354, 320.1, 357, 363, 366, 372, 372.3; 536/23.1 [IMAGE AVAILABLE]

74. 5,670,347, Sep. 23, 1997, Peptide-mediated gene transfer; T. Venkat Gopal, 435/467, 320.1 [IMAGE AVAILABLE]

75. 5,665,588, Sep. 9, 1997, DNA encoding natural killer lytic associated protein; Jackie Kornbluth, 435/348, 252.33, 320.1, 325, 372; 536/23.1, 23.5 [IMAGE AVAILABLE]

76. 5,662,896, Sep. 2, 1997, Compositions and methods for cancer immunotherapy; Jack R. Barber, et al., 424/93.2, 93.1; 435/320.1; 514/44 [IMAGE AVAILABLE]

77. 5,658,776, Aug. 19, 1997, Generation of high titers of recombinant AAV **vectors**; Terence R. Flotte, et al., 435/457, 91.4, 320.1, 352, 363, 366, 367, 369, 371 [IMAGE AVAILABLE]

78. 5,658,565, Aug. 19, 1997, Inducible nitric oxide synthase gene for treatment of disease; Timothy R. Billiar, et al., 424/93.21, 93.1, 93.2; 435/189, 191, 235.1, 320.1; 514/44; 536/23.1, 23.2, 23.5 [IMAGE AVAILABLE]

79. 5,652,224, Jul. 29, 1997, Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism; James M. Wilson, et al., 514/44; 424/93.21; 435/320.1, 325, 354, 366, 369, 370, 456 [IMAGE AVAILABLE]

80. 5,650,306, Jul. 22, 1997, Recombinant nucleic acids for inhibiting HIV gene expression; Gary J. Nabel, et al., 435/456, 320.1; 536/23.72, 24.1, 24.5 [IMAGE AVAILABLE]

81. 5,646,034, Jul. 8, 1997, Increasing rAAV titer; Michael Mamounas, et al., 435/325, 91.4, 320.1, 457 [IMAGE AVAILABLE]

82. 5,622,856, Apr. 22, 1997, High efficiency helper system for AAV **vector** production; Georges Natsoulis, 435/325, 69.1, 320.1, 348, 366, 367, 369; 536/23.72 [IMAGE AVAILABLE]

83. 5,616,487, Apr. 1, 1997, Stabilized **retrovirus** compositions; Bernhard O. Palsson, et al., 435/456, 235.1 [IMAGE AVAILABLE]

84. 5,589,377, Dec. 31, 1996, Recombinant **adeno-associated virus vectors**; Jane S. Lebkowski, et al., 435/369, 235.1, 320.1, 366, 367 [IMAGE AVAILABLE]

85. 5,552,309, Sep. 3, 1996, Use of polyols for improving the introduction of genetic material into cells; Keith L. March, 435/456; 424/93.1, 93.2, 426; 435/235.1, 320.1, 458; 514/44 [IMAGE AVAILABLE]

86. 5,550,019, Aug. 27, 1996, Methods of identifying compounds which alter apoptosis; John C. Reed, 435/6, 7.21 [IMAGE AVAILABLE]

87. 5,470,730, Nov. 2, 1995, Method for producing T.<sup>H</sup>-independent cytotoxic T lymphocytes, Phillip D. Greenberg, et al., 435/456; 424/93.21; 435/69.1, 69.52, 70.4, 252.3, 320.1 [IMAGE AVAILABLE]

88. 5,436,146, Jul. 25, 1995, Helper-free stocks of recombinant **adeno-associated virus vectors**; Thomas E. Shenk, et al., 435/457, 91.4, 235.1, 320.1, 367, 465; 536/23.72 [IMAGE AVAILABLE]

89. 5,354,678, Oct. 11, 1994, Production of recombinant **adeno-associated virus vectors**; Jane S. Lebkowski, et al., 435/463, 235.1, 320.1, 366, 367, 369, 372 [IMAGE AVAILABLE]